CDK12 and melanoma: To determine if the AP-1 pathway contributes to CDK12 inhibitor resistance, melanoma cells (A375 and Colo829) were treated with increasing concentrations of THZ531 in combination with two JNK inhibitors (AS601245 and JNK-IN-8)42.